PT1603578E - Tratamento de cistite com uma dose elevada de sulfato de condroitina - Google Patents

Tratamento de cistite com uma dose elevada de sulfato de condroitina Download PDF

Info

Publication number
PT1603578E
PT1603578E PT47119664T PT04711966T PT1603578E PT 1603578 E PT1603578 E PT 1603578E PT 47119664 T PT47119664 T PT 47119664T PT 04711966 T PT04711966 T PT 04711966T PT 1603578 E PT1603578 E PT 1603578E
Authority
PT
Portugal
Prior art keywords
treatment
high dose
chondroitin sulfate
interstitial cystitis
dose chondroitin
Prior art date
Application number
PT47119664T
Other languages
English (en)
Portuguese (pt)
Inventor
Peter R Riehl
Sungtack Samuel Hahn
Original Assignee
Tribute Pharmaceuticals Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1603578(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tribute Pharmaceuticals Canada Inc filed Critical Tribute Pharmaceuticals Canada Inc
Publication of PT1603578E publication Critical patent/PT1603578E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT47119664T 2003-02-19 2004-02-18 Tratamento de cistite com uma dose elevada de sulfato de condroitina PT1603578E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/367,970 US20040161476A1 (en) 2003-02-19 2003-02-19 Cystitis treatment with high dose chondroitin sulfate

Publications (1)

Publication Number Publication Date
PT1603578E true PT1603578E (pt) 2014-12-11

Family

ID=32850064

Family Applications (1)

Application Number Title Priority Date Filing Date
PT47119664T PT1603578E (pt) 2003-02-19 2004-02-18 Tratamento de cistite com uma dose elevada de sulfato de condroitina

Country Status (15)

Country Link
US (5) US20040161476A1 (fr)
EP (2) EP1603578B1 (fr)
JP (1) JP4778888B2 (fr)
CN (1) CN1758920B (fr)
AU (1) AU2004212650B2 (fr)
CA (1) CA2515512C (fr)
CY (1) CY1116069T1 (fr)
DE (1) DE14189577T9 (fr)
DK (1) DK1603578T3 (fr)
ES (1) ES2527664T3 (fr)
HK (2) HK1085136A1 (fr)
IL (2) IL170309A (fr)
PT (1) PT1603578E (fr)
SI (1) SI1603578T1 (fr)
WO (1) WO2004073584A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
WO2005058235A2 (fr) * 2003-12-10 2005-06-30 Keryx Biopharmaceuticals, Inc. Methodes utilisant le sulodexide dans le traitement des maladies de la vessie
ES2493626T3 (es) 2004-01-28 2014-09-12 The Regents Of The University Of California Nueva terapia intersticial para un alivio inmediato de los síntomas y terapia crónica en la cistitis intersticial
ITMI20061030A1 (it) * 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
US20090023637A1 (en) * 2006-08-30 2009-01-22 Parsons C Lowell Methods for detecting and treating interstitial cystitis
DE102006060953A1 (de) 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
WO2008144485A2 (fr) * 2007-05-18 2008-11-27 University Of Maryland, Baltimore Inhibition de l'expression et/ou de l'activité de palmitoyl acyle transférase pour la régulation d'activité du facteur antiprolifératif
US9849086B2 (en) 2012-03-19 2017-12-26 Nanologix Research, Inc. Method and composition for treating cystitis
CA2972866C (fr) * 2015-01-09 2023-08-22 Seikagaku Corporation Derive de l'acide chondroitine sulfurique et medicament pour le traitement de maladies de la vessie
CA3035659C (fr) * 2016-09-16 2022-09-06 Glycologix, Llc Biomateriaux a base de glycosaminoglycanes sulfates utilises en tant que mimetiques de proteoglycanes
EP3400950B1 (fr) 2017-05-12 2019-11-13 Farco-Pharma GmbH Composition d'instillation de la vessie contenant sulfate chondoitinique (20 mg/ml), acide hyaluronique (16 mg/ml) et tampon phosphate (ph 6,1 à 7.9) à stabilité au stockage améliorée pour le traitement de cystitis
DE202017103289U1 (de) 2017-05-12 2018-05-16 Farco-Pharma Gmbh Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer Wirkstoffkombination
DE202017103288U1 (de) 2017-05-12 2018-05-16 Farco-Pharma Gmbh Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer hochdosierten Wirkstoffkombination
EP3400951B1 (fr) 2017-05-12 2019-12-11 Farco-Pharma GmbH Composition d'instillation de la vessie contenant sulfate chondoitinique (4,5 mg/ml), acide hyaluronique (16 mg/ml) et tampon phosphate (ph 6,1 à 7.9) à stabilité au stockage améliorée pour le traitement de cystitis
EP3415163B1 (fr) 2017-06-13 2023-02-22 Farco-Pharma GmbH Composition présentant un effet anesthésique local et utilisation de celle-ci
DE202017104675U1 (de) 2017-06-13 2018-06-14 Farco-Pharma Gmbh Zusammensetzung mit lokalanästhetischer Wirkung und deren Verwendung
US20220370454A1 (en) * 2021-05-18 2022-11-24 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971955A (en) * 1981-03-02 1990-11-20 Soll David B Protection of human and animal cells during surgical trauma
FR2535324A1 (fr) * 1982-10-27 1984-05-04 Choay Sa Station perfectionnee pour l'epuration d'eaux usees
CA1187798A (fr) 1982-03-24 1985-05-28 David B. Soll Protection des cellules
AU555747B2 (en) 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
US4886786A (en) * 1985-08-01 1989-12-12 Lindstrom Richard L Additive for irrigation solution or surgical solution
EP0240098A3 (fr) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo et Polysaccharides pour le traitement des maladies causées par des rétrovirus
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
US5541166A (en) * 1987-01-23 1996-07-30 The Australian National University Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
US5037810A (en) * 1987-03-17 1991-08-06 Saliba Jr Michael J Medical application for heparin and related molecules
IT1217458B (it) * 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche
AU6872691A (en) 1989-10-27 1991-05-31 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
CA2020199C (fr) 1990-06-29 2002-08-20 Daniel Bar-Shalom Utilisation de sucres sulfates
DE4021066A1 (de) 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
CA2060223C (fr) 1991-02-12 1999-07-20 Clarence C. Lee Composition de fluide lubrifiant medical injectable et methode d'utilisation
IT1245907B (it) 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
IL102758A (en) 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
CA2100657A1 (fr) 1991-11-15 1993-05-16 Glen M. Hartung Methode de traitement des arthropathies algiques aigues et chroniques chez l'homme et chez d'autres mammiferes
EP0636631A1 (fr) * 1992-04-17 1995-02-01 Seikagaku Corporation Complexe de platine et agent antineoplasique
WO1994000135A1 (fr) 1992-06-30 1994-01-06 Shapiro Howard K Composition contenant des derives amines ou apparentes aux amines d'acide benzoique et utilisations, y compris dans le traitement de maladies inflammatoires
IT1264530B (it) * 1992-07-31 1996-10-02 Crinos Industria Farmaco Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
US6492349B1 (en) * 1993-03-31 2002-12-10 Nutramax Laboratories, Inc. Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
NZ260933A (en) 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
CA2130295A1 (fr) 1993-08-26 1995-02-27 Richard A. Berg Gels a glycosaminoglycanes reticulees a liaisons ioniques utilises pour l'augmentation des tissus mous et la liberation des principes actifs
AU698881B2 (en) 1994-05-11 1998-11-12 Howard K. Shapiro Compositions for treatment of chronic inflammatory diseases
IN181358B (fr) 1995-02-14 1998-05-30 Bioniche Inc
AUPN261895A0 (en) * 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
CA2232527C (fr) * 1995-09-19 2008-09-02 Seikagaku Corporation Agent anti-inflammatoire
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
US20030232100A1 (en) * 1998-04-08 2003-12-18 Theoharides Theoharis C. Compositions for treatment of diseases arising from secretion of mast cell biochemicals
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
CA2269260C (fr) 1999-04-16 2002-12-31 Stellar International Inc. Traitement de la cystite avec du sulfate de chondroitine
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
JP2001213784A (ja) * 2000-02-03 2001-08-07 Teisan Seiyaku Kk 乳牛の乳房炎治療剤
AU8136801A (en) * 2000-07-31 2002-02-13 Dermal Res Lab Inc Methods of preventing or treating diseases and conditions using complex carbohydrates
NZ540045A (en) * 2002-10-16 2008-04-30 Frank D Marcum Treatment for traumatic synovitis and damaged articular cartilage with chondroitin sulfate, N-acetyl D-glucosamine and hyaluronan
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US7485629B2 (en) * 2002-10-16 2009-02-03 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treatment of joint damage
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate

Also Published As

Publication number Publication date
US20100292182A1 (en) 2010-11-18
US20130143839A1 (en) 2013-06-06
WO2004073584A3 (fr) 2005-01-27
WO2004073584A2 (fr) 2004-09-02
HK1085136A1 (en) 2006-08-18
CA2515512C (fr) 2012-07-10
AU2004212650B2 (en) 2009-07-23
EP2857024A1 (fr) 2015-04-08
DK1603578T3 (en) 2015-01-19
US7772210B2 (en) 2010-08-10
DE14189577T1 (de) 2019-10-17
DE14189577T9 (de) 2020-12-10
IL238811A0 (en) 2015-06-30
SI1603578T1 (sl) 2015-04-30
US20120058969A1 (en) 2012-03-08
CA2515512A1 (fr) 2004-09-02
US20040161476A1 (en) 2004-08-19
AU2004212650A1 (en) 2004-09-02
JP4778888B2 (ja) 2011-09-21
EP1603578B1 (fr) 2014-10-29
JP2006517928A (ja) 2006-08-03
US20060194757A1 (en) 2006-08-31
CN1758920B (zh) 2010-05-26
IL238811A (en) 2017-03-30
EP1603578A2 (fr) 2005-12-14
CN1758920A (zh) 2006-04-12
ES2527664T3 (es) 2015-01-28
US8084441B2 (en) 2011-12-27
CY1116069T1 (el) 2017-02-08
US8334276B2 (en) 2012-12-18
IL170309A (en) 2015-11-30
US8778908B2 (en) 2014-07-15
HK1209037A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
HK1085136A1 (en) Treatment of interstitial cystitis with high dose chondroitin sulfate
IL166475A0 (en) Improved treatment of cancer with glutamine
EP1635813A4 (fr) Polytherapie permettant de traiter la dyslipidemie
IL169594A0 (en) Treatment of cancer with 2-deoxyglucose
HK1094875A1 (zh) 使用 治療苯丙酮尿症
GB0316912D0 (en) Therapeutic treatment
GB0201850D0 (en) Therapeutic treatment
GB0320806D0 (en) Therapeutic treatment
IL175689A0 (en) Enoxaparin for the treatment of cancer
GB0329275D0 (en) Therapeutic treatment
AU2003240545A8 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
GB0210464D0 (en) Therapeutic treatment
AU2003231803A8 (en) Treatment of cancer with mefloquire
GB0307863D0 (en) Therapeutic treatment
IL164951A0 (en) The treatment of pain with lfendropil
GB0313772D0 (en) Therapeutic treatment
GB0329416D0 (en) Treatment of cancer
IL180709A0 (en) Treatment of tumours
GB0327493D0 (en) Treatment medicament
PL372900A1 (en) Treatment of metabolic syndrome
GB0325957D0 (en) The treatment of pain
GB0208184D0 (en) Treatment by photodynamic therapy
GB0318552D0 (en) Therapeutic treatment
GB0321233D0 (en) Therapeutic treatment
GB0321650D0 (en) Therapeutic treatment